Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced receiving clinical trial approval from the Center for Drug Evaluation of China’s National Medical Products Administration (NMPA) for its small molecule inhibitor ABSK131. This follows a similar approval from US regulators in December of last year.
ABSK131: Promising Anti-Tumor Activity
ABSK131 is a small molecule inhibitor targeting PRMT5 and MTA, demonstrating strong anti-tumor activity. Preclinical studies have shown excellent selectivity towards MTAP deficient tumor cells, alongside good drug metabolism and pharmacokinetics.
Clinical Trial Outlook
The approval marks a significant milestone in the development of ABSK131, paving the way for further clinical evaluation in China. Abbisko Therapeutics plans to initiate clinical trials to assess the safety and efficacy of ABSK131 in patients with relevant cancers.-Fineline Info & Tech
Leave a Reply